Back to top
more

Nevro (NVRO)

(Delayed Data from NYSE)

$12.79 USD

12.79
412,366

+0.52 (4.24%)

Updated Apr 23, 2024 03:59 PM ET

After-Market: $12.81 +0.02 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott (ABT) Expands in Canada With First Eterna SCS Use

by Zacks Equity Research

Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw

by Zacks Equity Research

Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.

Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up

by Zacks Equity Research

Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.

Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 70% and 0.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q4 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update

by Zacks Equity Research

Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.

Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales

by Zacks Equity Research

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

Inogen (INGN) Down 4.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

What's in Store for Cooper Companies (COO) in Q4 Earnings?

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.

Wall Street Analysts Predict a 36.66% Upside in Nevro (NVRO): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Nevro (NVRO) points to a 36.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment

by Zacks Equity Research

Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.

Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.

Nevro (NVRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment

by Zacks Equity Research

Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS implant for durable pain relief and significant improvements in patient condition post-implantation.

Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.

Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.

Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of -1.47% and 0.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

MedTech Stocks to Watch for Earnings on Aug 1: ECL, NVRO, INSP

by Debanjana Dey

MedTech companies' Q2 results are likely to reflect strength in customer demand. Let's see how ECL, NVRO and INSP are placed ahead of their earnings releases.

Integer (ITGR) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Integer (ITGR) delivered earnings and revenue surprises of 15.15% and 8.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.